Jim Simons
RLMD icon

Jim Simons’s Relmada Therapeutics RLMD Stock Holding History

Jim Simons’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Sell
167,200
-17,800
-10% -$84.2K ﹤0.01% 2186
2025
Q4 		$894K Buy
185,000
+15,300
+9% +$51.3K ﹤0.01% 2342
2025
Q3 		$341K Buy
169,700
+19,600
+13% +$18.8K ﹤0.01% 2954
2025
Q2 		$90.1K Buy
150,100
+26,000
+21% +$13.3K ﹤0.01% 3319
2025
Q1 		$33.5K Sell
124,100
-40,413
-25% -$13.4K ﹤0.01% 3329
2024
Q4 		$85.5K Buy
164,513
+138,625
+535% +$338K ﹤0.01% 3307
2024
Q3 		$83.9K Sell
25,888
-62,887
-71% -$204K ﹤0.01% 3283
2024
Q2 		$266K Buy
88,775
+53,767
+154% +$195K ﹤0.01% 2953
2024
Q1 		$163K Sell
35,008
-111,881
-76% -$539K ﹤0.01% 3273
2023
Q4 		$608K Buy
146,889
+81,614
+125% +$242K ﹤0.01% 2697
2023
Q3 		$196K Sell
65,275
-67,497
-51% -$200K ﹤0.01% 3098
2023
Q2 		$327K Sell
132,772
-180,403
-58% -$499K ﹤0.01% 3091
2023
Q1 		$708K Buy
313,175
+95,365
+44% +$329K ﹤0.01% 2686
2022
Q4 		$760K Buy
+217,810
New +$1.91M ﹤0.01% 2690
2022
Q1 		– Sell
-14,400
Closed -$324K – 4395
2021
Q4 		$324K Sell
14,400
-1,100
-7% -$24.5K ﹤0.01% 3310
2021
Q3 		$406K Buy
+15,500
New +$415K ﹤0.01% 2967

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Jim Simons's RLMD Position: Q1 2026 in Review

Jim Simons reduced its Relmada Therapeutics (RLMD) stake by 9.6% in Q1 2026, selling an estimated $84.2K and leaving 167,200 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2186.

Jim Simons first reported a position in RLMD in Q3 2021 and has held it in 16 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Jim Simons held 167,200 shares of Relmada Therapeutics worth $1.16M as of Q1 2026.
  • Jim Simons sold 17,800 Relmada Therapeutics shares in Q1 2026, an estimated $84.2K.
  • Relmada Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2186 holding.
  • Jim Simons first reported a position in Relmada Therapeutics in Q3 2021 and has held it in 16 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.